Diasorin SpA (EUR)
DIA
Overview
Key Information
Legal Documents
Financials
Overview
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Day Range | 96.80 | 99.80 |
| 52-Wk Range | 68.60 | 111.00 |
| Last Close | 99.55 |
| Mkt Cap (m) | 5,447.64 |
| Dividend yield | 0.9% |
| ISIN | IT0003492391 |
| Volume | 145,555 |
| Exchange Venue | MIL |
Company Profile
Diasorin SpA is engaged in the development, manufacture and distribution ofimmunodiagnostics and molecular diagnostics tests.
Key Information
| Price/Earning | 33.98 |
| Price/Book | 7.29 |
| Price/Sales | 7.96 |
| P/CF | 25.58 |
| Rev Growth (3 year avg) | 10.26 |
| EPS Growth (3 year avg) | 0.16 |
| Operating Margin % | 31.36 |
| Net Margin % | 23.63 |
| Return on Equity | 21.87 |
| Debt/Equity | 0.03 |
Legal Documents
Annual Report
| en 31/12/2017 |
Financials
Income Statement
| EUR | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
| Revenue (m) | 435 | 444 | 499 | 569 | 637 | 669 |
| Operating Income (m) | 137 | 132 | 156 | 178 | 198 | 210 |
| Net Income (m) | 83 | 84 | 100 | 112 | 140 | 158 |
| Basic EPS | 1.53 | 1.55 | 1.83 | 2.05 | 2.54 | 2.85 |
| Avg. Diluted Shares Outstanding (m) | 54 | 54 | 55 | 55 | 55 | 56 |
Balance Sheet
| EUR | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
| Current Assets (m) | 318 | 391 | 494 | 395 | 482 | 415 |
| Non Current Assets (m) | 209 | 215 | 214 | 473 | 460 | 491 |
| Total Assets (m) | 527 | 606 | 708 | 869 | 946 | 906 |
| Current Liabilities (m) | 78 | 82 | 82 | 132 | 141 | 138 |
| Total Liabilities (m) | - | - | - | - | - | - |
| Total Equity (m) | 414 | 483 | 587 | 663 | 741 | 705 |
Cash Flows
| EUR | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
| Operating Cash Flows (m) | 108 | 120 | 138 | 166 | 167 | 210 |
| Capital Expenditure (m) | -32 | -31 | -32 | -37 | -42 | -53 |
Figures are quoted in EUR unless stated otherwise
-2.60 (-2.61%)
€
96.95
Last Price
© 2019 MeDirect Bank (Malta) plc. All rights reserved.